Month: March 2019

Pre-Clinical Model Showed Delayed Tumor Growth in the Presence of UBM™ Particulate Columbia, MD — (March 25, 2019) – MimiClon, Inc. today announced publication of the article entitled “A biologic scaffold-associated type 2 immune microenvironment inhibits tumor formation and synergizes with checkpoint immunotherapy” in the journal Science Translational Medicine. The research was led by Matthew […]

Columbia, MD— (March 18, 2019) MimiClon, Inc. today announced that it has entered into an exclusive distribution agreement with MyungMoon Bio Co. Ltd. MyungMoon is a leading manufacturer and distributor of medical devices and pharmaceutical products in South Korea. The terms of the distribution agreement grant exclusive rights to MyungMoon for the sale, marketing, and […]